Thyroid Cancer

Thyroid cancer encompasses papillary (85%), follicular, medullary, and anaplastic subtypes with vastly different biology and prognoses. BRAF V600E mutation in anaplastic thyroid cancer predicts response to dabrafenib + trametinib. RET-targeted therapies (selpercatinib, pralsetinib) have transformed medullary thyroid cancer. Sorafenib and lenvatinib extend progression-free survival in radioactive iodine–refractory differentiated thyroid cancer.

Approved drugs, investigational agents, and relevant clinical trials for this disease area.

Approved Drugs for Thyroid Cancer

• Sorafenib (Nexavar) — Tyrosine Kinase Inhibitor
• Lenvatinib (Lenvima) — Tyrosine Kinase Inhibitor
• Cabozantinib (Cabometyx) — Tyrosine Kinase Inhibitor
• Selpercatinib (Retevmo) — Tyrosine Kinase Inhibitor
• Pralsetinib (Gavreto) — Tyrosine Kinase Inhibitor
• Larotrectinib (Vitrakvi) — Tyrosine Kinase Inhibitor
• Dabrafenib (Tafinlar) — Tyrosine Kinase Inhibitor
• Trametinib (Mekinist) — Tyrosine Kinase Inhibitor